Contact
searchSearch
HMP Global
Login

HR-Positive, HER2-Negative Breast Cancer Specialty Channel

HR+/HER2– Breast Cancer
Specialty Channel
William Gradishar, MD, Robert H Lurie Comprehensive Cancer Center
Videos
Extended Endocrine Therapy for Patients With Hormone Receptor-Positive, Early-Stage Breast Cancer
03/06/2025
William Gradishar, MD
William Gradishar, MD, discusses the issue of endocrine therapy, and extended endocrine therapy, for patients with hormone receptor-positive breast cancer.
William Gradishar, MD, discusses the issue of endocrine therapy, and extended endocrine therapy, for patients with hormone receptor-positive breast cancer.
William Gradishar, MD, discusses...
03/06/2025
Oncology
News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
Allison Casey
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
Conference Coverage
Palbociclib Plus Endocrine Therapy Improved Time to Treatment Failure, Survival Outcomes for Patients With High-Risk HR-Positive, HER2-Negative Metastatic Breast Cancer
12/03/2024
Allison Casey
According to a phase 3 trial, palbociclib plus endocrine therapy improved time to treatment failure and survival outcomes among patients with high-risk hormone receptor-positive, HER2-negative metastatic breast cancer.
According to a phase 3 trial, palbociclib plus endocrine therapy improved time to treatment failure and survival outcomes among patients with high-risk hormone receptor-positive, HER2-negative metastatic breast cancer.
According to a phase 3 trial,...
12/03/2024
Oncology
News
Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients With HR-Positive, HER2-Negative Breast Cancer
10/29/2024
Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.
Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.
Primary results from the...
10/29/2024
Oncology
Conference Coverage
First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
10/18/2024
Stephanie Holland
Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.
Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.
Results from the phase 2 ABIGAIL...
10/18/2024
Oncology
Conference Coverage
Addition of Ribociclib Decreases Risk of Invasive and Distant Disease Recurrence Among Patients With HR-Positive, HER2-Negative Breast Cancer
10/04/2024
Stephanie Holland
Landmark 4-year analysis results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment significantly decreases the risk of invasive and distant disease recurrence among...
Landmark 4-year analysis results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment significantly decreases the risk of invasive and distant disease recurrence among...
Landmark 4-year analysis results...
10/04/2024
Oncology
News
First-Line Ribociclib Plus Endocrine Therapy Significantly Improved PFS Among Pre-Menopausal Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
07/11/2024
Stephanie Holland
Results from the phase 2 RIGHT Choice trial demonstrated that first-line ribociclib plus endocrine therapy significantly improved progression-free survival with similar response rates and better tolerability compared to chemotherapy among...
Results from the phase 2 RIGHT Choice trial demonstrated that first-line ribociclib plus endocrine therapy significantly improved progression-free survival with similar response rates and better tolerability compared to chemotherapy among...
Results from the phase 2 RIGHT...
07/11/2024
Oncology
Kevin Kalinsky, MD, Winship Cancer Institute
Videos
Abemaciclib Added to Fulvestrant Improved Progression-Free Survival for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
06/13/2024
Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...
Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...
Kevin Kalinsky, MD, shares...
06/13/2024
Oncology
Conference Coverage
Pembrolizumab Plus Sacituzumab Govitecan for Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer
06/06/2024
Allison Casey
According to results from a phase 2 trial, pembrolizumab added to sacituzumab govitecan showed a non-significant trend toward improvement in progression-free survival among patients with HR-positive, HER2-negative metastatic breast cancer.
According to results from a phase 2 trial, pembrolizumab added to sacituzumab govitecan showed a non-significant trend toward improvement in progression-free survival among patients with HR-positive, HER2-negative metastatic breast cancer.
According to results from a...
06/06/2024
Oncology

News

News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
Allison Casey
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
Conference Coverage
Palbociclib Plus Endocrine Therapy Improved Time to Treatment Failure, Survival Outcomes for Patients With High-Risk HR-Positive, HER2-Negative Metastatic Breast Cancer
12/03/2024
Allison Casey
According to a phase 3 trial, palbociclib plus endocrine therapy improved time to treatment failure and survival outcomes among patients with high-risk hormone receptor-positive, HER2-negative metastatic breast cancer.
According to a phase 3 trial, palbociclib plus endocrine therapy improved time to treatment failure and survival outcomes among patients with high-risk hormone receptor-positive, HER2-negative metastatic breast cancer.
According to a phase 3 trial,...
12/03/2024
Oncology
News
Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients With HR-Positive, HER2-Negative Breast Cancer
10/29/2024
Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.
Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.
Primary results from the...
10/29/2024
Oncology
Conference Coverage
First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
10/18/2024
Stephanie Holland
Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.
Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.
Results from the phase 2 ABIGAIL...
10/18/2024
Oncology
Conference Coverage
Addition of Ribociclib Decreases Risk of Invasive and Distant Disease Recurrence Among Patients With HR-Positive, HER2-Negative Breast Cancer
10/04/2024
Stephanie Holland
Landmark 4-year analysis results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment significantly decreases the risk of invasive and distant disease recurrence among...
Landmark 4-year analysis results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment significantly decreases the risk of invasive and distant disease recurrence among...
Landmark 4-year analysis results...
10/04/2024
Oncology
News
First-Line Ribociclib Plus Endocrine Therapy Significantly Improved PFS Among Pre-Menopausal Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
07/11/2024
Stephanie Holland
Results from the phase 2 RIGHT Choice trial demonstrated that first-line ribociclib plus endocrine therapy significantly improved progression-free survival with similar response rates and better tolerability compared to chemotherapy among...
Results from the phase 2 RIGHT Choice trial demonstrated that first-line ribociclib plus endocrine therapy significantly improved progression-free survival with similar response rates and better tolerability compared to chemotherapy among...
Results from the phase 2 RIGHT...
07/11/2024
Oncology
Kevin Kalinsky, MD, Winship Cancer Institute
Videos
Abemaciclib Added to Fulvestrant Improved Progression-Free Survival for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
06/13/2024
Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...
Kevin Kalinsky, MD, shares results from the phase 3 postMONARCH trial evaluating the continuation of CDK4/6 inhibition plus an aromatase inhibitor for patients with advanced breast cancer who had progressed on prior CDK4/6 inhibition and...
Kevin Kalinsky, MD, shares...
06/13/2024
Oncology
Conference Coverage
Pembrolizumab Plus Sacituzumab Govitecan for Patients With HR-Positive, HER2-Negative Metastatic Breast Cancer
06/06/2024
Allison Casey
According to results from a phase 2 trial, pembrolizumab added to sacituzumab govitecan showed a non-significant trend toward improvement in progression-free survival among patients with HR-positive, HER2-negative metastatic breast cancer.
According to results from a phase 2 trial, pembrolizumab added to sacituzumab govitecan showed a non-significant trend toward improvement in progression-free survival among patients with HR-positive, HER2-negative metastatic breast cancer.
According to results from a...
06/06/2024
Oncology

Recent News

News
Datopotamab Deruxtecan Approved for HR-Positive, HER2-Negative Breast Cancer
01/17/2025
Allison Casey
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug Administration approved datopotamab deruxtecan for the treatment of patients with unresectable or metastatic, HR-positive, HER2-negative breast cancer who have received prior endocrine-based therapy and chemotherapy in...
The US Food and Drug...
01/17/2025
Oncology
Conference Coverage
Palbociclib Plus Endocrine Therapy Improved Time to Treatment Failure, Survival Outcomes for Patients With High-Risk HR-Positive, HER2-Negative Metastatic Breast Cancer
12/03/2024
Allison Casey
According to a phase 3 trial, palbociclib plus endocrine therapy improved time to treatment failure and survival outcomes among patients with high-risk hormone receptor-positive, HER2-negative metastatic breast cancer.
According to a phase 3 trial, palbociclib plus endocrine therapy improved time to treatment failure and survival outcomes among patients with high-risk hormone receptor-positive, HER2-negative metastatic breast cancer.
According to a phase 3 trial,...
12/03/2024
Oncology
News
Datopotamab Deruxtecan Significantly Improves Progression-Free Survival for Patients With HR-Positive, HER2-Negative Breast Cancer
10/29/2024
Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.
Primary results from the TROPION-Breast01 trial demonstrated that datopotamab deruxtecan significantly improved progression-free survival for patients with HR-positive, HER2-negative breast cancer.
Primary results from the...
10/29/2024
Oncology
Conference Coverage
First-Line Abemaciclib Plus Endocrine Therapy Improves Efficacy Among Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
10/18/2024
Stephanie Holland
Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.
Results from the phase 2 ABIGAIL trial demonstrated that first-line abemaciclib plus endocrine therapy improves efficacy compared to standard chemotherapy among patients with HR-positive, HER2-negative advanced breast cancer.
Results from the phase 2 ABIGAIL...
10/18/2024
Oncology
Conference Coverage
Addition of Ribociclib Decreases Risk of Invasive and Distant Disease Recurrence Among Patients With HR-Positive, HER2-Negative Breast Cancer
10/04/2024
Stephanie Holland
Landmark 4-year analysis results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment significantly decreases the risk of invasive and distant disease recurrence among...
Landmark 4-year analysis results from the phase 3 NATALEE trial demonstrated that the addition of ribociclib to nonsteroidal aromatase inhibitor treatment significantly decreases the risk of invasive and distant disease recurrence among...
Landmark 4-year analysis results...
10/04/2024
Oncology
News
First-Line Ribociclib Plus Endocrine Therapy Significantly Improved PFS Among Pre-Menopausal Patients With HR-Positive, HER2-Negative Advanced Breast Cancer
07/11/2024
Stephanie Holland
Results from the phase 2 RIGHT Choice trial demonstrated that first-line ribociclib plus endocrine therapy significantly improved progression-free survival with similar response rates and better tolerability compared to chemotherapy among...
Results from the phase 2 RIGHT Choice trial demonstrated that first-line ribociclib plus endocrine therapy significantly improved progression-free survival with similar response rates and better tolerability compared to chemotherapy among...
Results from the phase 2 RIGHT...
07/11/2024
Oncology
News
Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma
04/02/2025
Emily Estrada
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.
At a tolerable and safe dose,...
04/02/2025
Oncology
News
Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma
04/02/2025
Emily Estrada
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.
Quadruplet therapy with...
04/02/2025
Oncology
News
Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma
04/02/2025
Emily Estrada
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.
The presence of 2 or more...
04/02/2025
Oncology
News
Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases
04/01/2025
Stephanie Holland
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.
According to results from a...
04/01/2025
Oncology
News
Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer
04/01/2025
Allison Casey
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.
According to a retrospective...
04/01/2025
Oncology
News
Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer
04/01/2025
Allison Casey
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.
A study found the addition of...
04/01/2025
Oncology
News
Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors
03/31/2025
Janelle Bradley
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.
Findings from a phase 2 study...
03/31/2025
Oncology
FDA Approval
Durvalumab Approved for Muscle Invasive Bladder Cancer
03/31/2025
Allison Casey
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.
The US FDA approved neoadjuvant...
03/31/2025
Oncology
FDA Approval
FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer
03/28/2025
Stephanie Holland
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...
Based on results from the...
03/28/2025
Oncology
FDA Approval
FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs
03/26/2025
Stephanie Holland
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...
Based on results from the...
03/26/2025
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use